Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913350 | 0.93 | MAPT (0.59) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL2904593 | 0.91 | MAPT (0.64) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL23575246 | 0.91 | MAPT (0.61) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL2912196 | 0.88 | CSF1R (0.64) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL2913279 | 0.88 | CSF1R (0.64) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL2910297 | 0.85 | MAPT (0.59) | MAPTTP53GAATHRBCSF1R | |
| SCHEMBL4906661 | 0.85 | MAPT (0.69) | MAPTTP53GAATHRBSMN1; SMN2 | |
| SCHEMBL23575685 | 0.84 | MAPT (0.55) | MAPTTP53GAATHRBSMN1; SMN2 | |
| SCHEMBL2908163 | 0.84 | CSF1R (0.64) | MAPTTP53PAX8GAATHRB | |
| SCHEMBL5929672 | 0.83 | MAPT (0.65) | MAPTTP53GAATHRBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-2084134-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056148-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | MAPT 3172/4885TP53 928/4885PAX8 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.